Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 6
2011 3
2012 2
2013 2
2014 1
2015 2
2018 1
2021 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Health literacy and antiretroviral adherence among HIV-infected adolescents.
Murphy DA, Lam P, Naar-King S, Robert Harris D, Parsons JT, Muenz LR; Adolescent Medicine Trials Network for HIV/AIDS Interventions. Murphy DA, et al. Patient Educ Couns. 2010 Apr;79(1):25-9. doi: 10.1016/j.pec.2009.07.014. Epub 2009 Aug 8. Patient Educ Couns. 2010. PMID: 19665860 Free PMC article.
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants.
McFarland EJ, Cunningham CK, Muresan P, Capparelli EV, Perlowski C, Morgan P, Smith B, Hazra R, Purdue L, Harding PA, Theron G, Mujuru H, Agwu A, Purswani M, Rathore MH, Flach B, Taylor A, Lin BC, McDermott AB, Mascola JR, Graham BS; International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) P1112 Team. McFarland EJ, et al. J Infect Dis. 2021 Dec 1;224(11):1916-1924. doi: 10.1093/infdis/jiab229. J Infect Dis. 2021. PMID: 34009371 Free PMC article.
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.
Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team. Nachman S, et al. Clin Infect Dis. 2014 Feb;58(3):413-22. doi: 10.1093/cid/cit696. Epub 2013 Oct 21. Clin Infect Dis. 2014. PMID: 24145879 Free PMC article. Clinical Trial.
Patterns of disclosure among youth who are HIV-positive: a multisite study.
Dempsey AG, MacDonell KE, Naar-King S, Lau CY; Adolescent Medicine Trials Network for HIV/AIDS Interventions. Dempsey AG, et al. J Adolesc Health. 2012 Mar;50(3):315-7. doi: 10.1016/j.jadohealth.2011.06.003. Epub 2011 Sep 3. J Adolesc Health. 2012. PMID: 22325140 Free PMC article.
Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Harris DR, Price G, Baker A, Meyer WA 3rd, Wilson CM, Hazra R, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team. Havens PL, et al. Clin Infect Dis. 2018 Jan 6;66(2):220-228. doi: 10.1093/cid/cix753. Clin Infect Dis. 2018. PMID: 29020329 Free PMC article. Clinical Trial.
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.
Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM, Smith E, Graham B, Mathew M, Aldrovani G; PACTG 1020A Study Team. Rutstein RM, et al. Pediatr Infect Dis J. 2015 Feb;34(2):162-7. doi: 10.1097/INF.0000000000000538. Pediatr Infect Dis J. 2015. PMID: 25232777 Free PMC article. Clinical Trial.
15 results